Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2018’, provides an overview of the Idiopathic Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis

- The report reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects

- The report assesses Idiopathic Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeome Corp

AdAlta Ltd

Aeolus Pharmaceuticals Inc

Amplia Therapeutics Ltd

AnaMar AB

apceth Biopharma GmbH

Asahi Kasei Corp

BerGenBio ASA

Biogen Inc

Bioneer Corp

Boehringer ...

Abeome Corp

AdAlta Ltd

Aeolus Pharmaceuticals Inc

Amplia Therapeutics Ltd

AnaMar AB

apceth Biopharma GmbH

Asahi Kasei Corp

BerGenBio ASA

Biogen Inc

Bioneer Corp

Boehringer Ingelheim GmbH

BreStem Therapeutics Inc

Bristol-Myers Squibb Co

Celdara Medical LLC

Celgene Corp

Certa Therapeutics Pty Ltd

Chiesi Farmaceutici SpA

Compugen Ltd

Cynata Therapeutics Ltd

FibroGen Inc

FibroStatin SL

Galapagos NV

Galecto Biotech AB

GenKyoTex SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Global Blood Therapeutics Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

iBio Inc

Inventiva

Isarna Therapeutics GmbH

Kadmon Corp LLC

KBP BioSciences Co Ltd

Kyorin Pharmaceutical Co Ltd

LifeMax Laboratories Inc

Lung Therapeutics Inc

Medicenna Therapeutics Corp

Miragen Therapeutics Inc

Mission Therapeutics Ltd

Moerae Matrix Inc

Novartis AG

Novo Nordisk AS

Nuevolution AB

Nuformix Plc

OliX Pharmaceuticals Inc

Onspira Therapeutics Inc

Pharmaxis Ltd

Pliant Therapeutics Inc

Promedior Inc

ProMetic Life Sciences Inc

Pulmatrix Inc

Re-Pharm Ltd

Redx Pharma Plc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

Ribomic Inc

Saje Pharma LLC

Samumed LLC

Shionogi & Co Ltd

Sorrento Therapeutics Inc

Taiho Pharmaceutical Co Ltd

Telocyte LLC

Therabron Therapeutics Inc

Unity Biotechnology Inc

Vicore Pharma AB

X-Rx Inc

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Idiopathic Pulmonary Fibrosis - Overview 7

Idiopathic Pulmonary Fibrosis - Therapeutics Development 8

Idiopathic Pulmonary Fibrosis ...

Table of Contents

Table of Contents 2

Introduction 6

Idiopathic Pulmonary Fibrosis - Overview 7

Idiopathic Pulmonary Fibrosis - Therapeutics Development 8

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 24

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 38

Idiopathic Pulmonary Fibrosis - Drug Profiles 68

Idiopathic Pulmonary Fibrosis - Dormant Projects 316

Idiopathic Pulmonary Fibrosis - Discontinued Products 320

Idiopathic Pulmonary Fibrosis - Product Development Milestones 321

Appendix 332

List of Tables

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Amplia Therapeutics Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Corp, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by BerGenBio ASA, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by BreStem Therapeutics Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Celdara Medical LLC, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Certa Therapeutics Pty Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Galecto Biotech AB, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by KBP BioSciences Co Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by LifeMax Laboratories Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Medicenna Therapeutics Corp, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Miragen Therapeutics Inc, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Mission Therapeutics Ltd, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports